Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,528JPY
24 Jan 2017
Change (% chg)

¥-3 (-0.20%)
Prev Close
¥1,530
Open
¥1,526
Day's High
¥1,540
Day's Low
¥1,524
Volume
6,235,200
Avg. Vol
7,583,376
52-wk High
¥1,779
52-wk Low
¥1,358

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.59
Market Cap(Mil.): ¥3,296,426.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 2.16

Financials

  4503.T Industry Sector
P/E (TTM): 15.88 28.98 29.85
EPS (TTM): 96.36 -- --
ROI: 15.22 15.43 14.85
ROE: 16.14 16.63 16.28

Synergy wins U.S. approval for constipation drug

The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

Jan 19 2017

UPDATE 1-Synergy wins U.S. approval for constipation drug

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

Jan 19 2017

BRIEF-Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs

* Says co terminates agreement with UMN Pharma Inc , for the co-development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan

Jan 10 2017

BRIEF-Astellas to acquire Ganymed Pharmaceuticals 422 mln euros

* Atellas will pay eur 422 million to acquire 100% of equity in Gnymed

Oct 28 2016

BRIEF-Astellas to buy Ganymed Pharmaceuticals for 422 mln euros

* Astellas says to buy Ganymed Pharmaceuticals for EUR 422 million ($460 million)

Oct 27 2016

BRIEF-Astellas Pharma Inc's operating profit likely rose roughly 20% on the year for April-September half - Nikkei

* Astellas Pharma Inc's operating profit likely rose roughly 20% on the year to 160 billion yen ($1.54 billion) or so for April-September half - Nikkei

Oct 21 2016

Fitch Assigns First-Time 'BBB-' Rating to Beijing Capital Development

(The following statement was released by the rating agency) HONG KONG, October 20 (Fitch) Fitch Ratings has assigned Beijing Capital Development Holding (Group) Co., Ltd. (known by its abbreviated Chinese name Shokai Group) a Long-Term Foreign-Currency Issuer Default Rating (IDR) of 'BBB-' with Stable Outlook. Fitch has also assigned the homebuilder a foreign-currency senior unsecured rating of 'BBB-'. Fitch has also assigned Bright Galaxy International Limited's (Bright Galaxy) proposed US

Oct 20 2016

BRIEF-Astellas Pharma files lawsuit against patent infringement of Myrbetriq in U.S.

* Says the co and its subsidiaries jointly filed a lawsuit with the United States District Court against Actavis Elizabeth LLC and its affiliates, who filed an abbreviated new drug application for a generic version of Astellas' mirabegron (generic name) product sold under the trademark Myrbetriq in the U.S.

Oct 06 2016

BRIEF-Cytokinetics announces early termination of Hart-Scott-Rodino waiting period

* Announces Early Termination Of Hart-Scott-Rodino waiting period for expanded collaboration with astellas

Sep 29 2016

BRIEF-Astellas Pharma gets approval for medicine for hyperphosphatemia in Japan

* Says the co received a marketing approval of Kiklin Granules 86.2% for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease in Japan

Sep 28 2016

Earnings vs. Estimates